Tremelimumab & Teclistamab
Oct 27, 2022•23 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
New Drug Approvals!
-Tremelimumab, the 2nd CTLA-4 inhibitor, finally gets approved.
-Teclistamab, an excited BCMA-CD3 T-cell engager for multiple myeloma.
For the best experience, listen in Metacast app for iOS or Android